Risk Assessment Tool for Distant Recurrence After Platinum-Based Concurrent Chemoradiation in Patients With Locally Advanced Cervical Cancer: A Korean Gynecologic Oncology Group Study

Abstract

We have developed a robust model to predict the risk of distant recurrence in patients with locally advanced cervical cancer. Further, we discussed how the selective enrichment of the patient population could facilitate clinical trials of systemic chemotherapy in locally advanced cervical cancer.

Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy

“…Nevertheless, PET/CT seems to be better at identifying extrapelvic disease and nodal metastasis than conventional CT or MRI [29]. A recent study by Kang et al introduced a risk assessment model that predicted distant recurrence in LACC [30]. The authors selected four variables, including histology, tumor size, and pelvic/paraaortic lymph node metastasis on PET/CT.…”

Establishing a Nomogram for Stage IA-IIB Cervical Cancer Patients after Complete Resection

“…Nomograms that have been constructed to focus on cervical cancer patients of advanced stages who are receiving concurrent chemoradiotherapy (Tseng et al, 2010;Kang et al, 2012). However, no nomogram emphasizing on patients primarily treated with surgery has been developed thus far.…”

Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer

“…Similar to our findings, previous studies showed more accurate predictive ability of models that included qualitative imaging parameters and clinical-pathological factors compared to FIGO stage alone. However, these studies focused only on high-risk cohorts of patients with LACC treated with definitive chemoradiation-therapy 5,14 thus unable to construct a prognostic model which is, by definition, independent of treatment received. Only one previous study constructed and validated a prognostic model of clinical-pathological factors alone (with no added imaging findings) in a large cohort of cervical cancer patients including FIGO stage I to IV 8 .…”

“…Few previous reports have simultaneously analyzed the prognostic value of multiple variables (including imaging findings) in patients with cervical cancer to create a nomogram able to provide individualized prediction of outcome 5–9 . These nomograms which include age, histologic type, tumor size, parametrial involvement, pelvic organ invasion and LN status, have been shown to compare favorably with FIGO staging system.…”

“…These nomograms which include age, histologic type, tumor size, parametrial involvement, pelvic organ invasion and LN status, have been shown to compare favorably with FIGO staging system. In patients with locally advanced cervical cancer (LACC), Kang et al 5 developed a four-parameter risk assessment model to predict recurrence, which included pelvic/paraaortic LN metastasis detected on 18F-fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) and clinical-histopathological factors. In contrast, Shim SH et al 9 introduced a three variable risk assessment model to predict 5-year survival in patients with LACC, which incorporated histology, tumor size, and paraaortic LN metastasis detected on MRI.…”